The effects of temocillin and moxalactam on platelet responsiveness and bleeding time were examined in healthy male volunteers. In the first study, moxalactam (4 g intravenously every 12 h) was given to six subjects; template bleeding times were at least doubled in five subjects 12 to 14 h after 7 doses (P = 0.008) and in all six subjects 12 to 14 h after 13 doses (P = 0.004). ADP-induced primary aggregation was approximately halved after 7 (P = 0.026) and 13 doses (P = 0.008), and there was a markedly increased tendency toward disaggregation. Collagen-induced aggregation was also halved, but the effect only reached statistical significance after 13 doses (P = 0.008). There was essentially no effect on primary aggregation in response to the thromboxane receptor agonist U46619 or to platelet activating factor. Temocillin (4 g intravenously every 12h) was given to eight subjects, three of whom had participated in the moxalactam study 8 weeks earlier.Temocillin had no significant effect on template bleeding time 12 to 14 h after 7 or 13 doses. However, in four subjects, the endpoint may have been less abrupt. There was no significant effect on ADP-induced primary aggregation or responsiveness to collagen. Even after 13 doses of temocillin, secondary aggregation in response to normal concentrations of ADP was demonstrable in the platelet-rich plasma of all eight subjects. Neither antibiotic had any effect on prothrombin times. Thus, with methodology that readily detected the effects of moxalactam on hemostasis, we were unable to demonstrate any unequivocal deleterious effects of temocillin at its maximum recommended dose. Temocillin may therefore be particularly useful for the treatment of many gram-negative infections in patients at increased risk of clinical bleeding.Recent reports on bleeding complications in patients treated with cephalosporins have focused attention once again on the unwanted hematological effects of P-lactam antibiotics in general and new ones in particular (13, 16). Temocillin (BRL 17421) is a new semisynthetic P-lactam antibiotic that is exceptionally stable to a wide range of ,-lactamases and, unlike the majority of penicillins, has a relatively long half-life (3.5 to 5 h) in sera of normal subjects (3, 15). The study described here was designed to examine the effect of temocillin on platelet responsiveness and bleeding time in healthy volunteers when given intravenously at the maximum recommended dose for 7 days. However, it was preceded by a similar study of moxalactam for two reasons. First, we needed to establish that our methodology would detect the effects expected of a ,-lactam antibiotic. Moxalactam was selected for this because it has well-documented activity at doses similar to those to be used in the temocillin study (16 exclusion criteria included known history of penicillin allergy, gastrointestinal tract ulceration, or coagulation defects. All subjects denied having taken aspirin in the 10 days preceding each study. Alcohol and strenuous exercise were prohibited throughout the...